Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.645 +0.075 (+4.78%)
Streaming Delayed Price Updated: 3:46 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

< Previous 1 2 3 4 5 Next >
Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From Law Offices of Frank R. Cruz
Via Business Wire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements
EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Top movers in Wednesday's pre-market session
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week
Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025. 
Via Stocktwits
Which stocks are gapping on Thursday?
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A’s Backbone Therapy Strategy
New York, NY – March 20, 2025 – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has... 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024
ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
 
Via Benzinga
Topics Stocks
Dow Tumbles 950 Points; ISM Services PMI Surges In July
 
Via Benzinga
Topics Stocks
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequate support despite achieving a statistically significant primary endpoint. Actinium... 
Via Benzinga
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
 
Via Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis. 
Via InvestorPlace
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
These are the clinical-stage biotech stocks to buy, as they represent companies with an attractive product pipeline. 
Via InvestorPlace
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
Via Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Via AB Newswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first... 
Via Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin... 
Via FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
Via AB Newswire
Topics Intellectual Property
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.